ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the translational medicine and Phase Ib clinical trial (NCT03594422) of its proprietary Class 1 new drug, olverembatinib (brand name: Narlix®), for treating gastrointestinal stromal tumors (GIST), were published in the internationally renowned journal *Signal Transduction and Targeted Therapy* (impact factor: 52.7). The study demonstrated olverembatinib's efficacy and safety in succinate dehydrogenase (SDH)-deficient GIST and, for the first time, revealed its novel anti-tumor mechanism through lipid metabolism regulation.

The Phase I trial evaluated olverembatinib's safety and anti-tumor activity in 66 patients with unresectable/metastatic GIST or other solid tumors, including 26 SDH-deficient GIST patients who had failed tyrosine kinase inhibitor (TKI) therapy. This marks the largest prospective clinical trial to date for this rare GIST subtype.